AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01193842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01193842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01193842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01193842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01193842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT01193842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01193842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01193842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03423134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a strip made of a newly developed adhesive
Study NCT03764085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheosorbilact®
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Study NCT03764085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study NCT02517216 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight
Study NCT02517216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT03318666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Our Valued Adolescents (SOVA)
Description: The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments.
Study NCT03318666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
Study NCT03318666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
Study NCT03755388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Episealer
Description: Placing Episealer device
Study NCT00816114 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Investigator review of MDACC CML patient charts.
Study NCT00976677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00976677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00976677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00976677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00976677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00976677 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV
Study NCT00976677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT04552925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Exercises and rehabilitation for massive rotator cuff tears
Study NCT04552925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Exercises and rehabilitation for massive rotator cuff tears
Study NCT03950791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Class
Description: A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.
Study NCT03950791 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: Education about improving lifestyle factors to improve participants' overall health.
Study NCT03747419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.
Study NCT03747419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Cancer treatment that uses ionizing radiation to kill cancer cells.
Study NCT01067521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Description: GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
Study NCT01067521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer acetate (GA)
Description: GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
Study NCT01067521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
Study NCT03405064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Levonadifloxacin/Linezolid Tablet
Description: oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
Study NCT03405064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Levonadifloxacin/Linezolid Tablet
Description: oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
Study NCT05821894 — intervention group
Intervention type: OTHER
Intervention: Observational study
Study NCT03290079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
Study NCT03290079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg Lenvatinib by mouth every day of each 3 week cycle
Study NCT03605927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986004
Description: BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
Study NCT03605927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.
Study NCT03605927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.
Study NCT03802227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181
Description: A combination of NKTR-181 and oxycodone IR placebo
Study NCT03802227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone IR
Description: A combination of oxycodone IR and NKTR-181 placebo
Study NCT04676854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMA Bionic Vision System
Description: Implantation of PRIMA, Vision training, follow up
Study NCT03405064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Levonadifloxacin/Linezolid Infusion
Description: IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
Study NCT03405064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Levonadifloxacin/Linezolid Infusion
Description: IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
Study NCT04566549 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Test group Probiotic Shampoo
Description: Probiotic Shampoo
Study NCT04566549 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Shampoo base
Study NCT02077335 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy monotherapy
Description: Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 > 95%~* V150 30-35%~* V200 \< 15%~* D90 > 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure.
Study NCT04060849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nozin
Description: Given via nasal single-use popswabs or single-use cotton tipped applicators
Study NCT04060849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT06680505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 10mg
Description: YZJ-1139 10mg tablets
Study NCT06680505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 20mg
Description: YZJ-1139 20mg tablets
Study NCT06680505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 40mg
Description: YZJ-1139 40mg tablets
Study NCT06680505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 60mg
Description: YZJ-1139 60mg tablets
Study NCT06680505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match placebo tablets
Study NCT04472468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Balloon Pericardiotomy
Description: * Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.
Study NCT02176616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: linear ablation
Description: The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
Study NCT02176616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation
Description: The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
Study NCT03274336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: movie
Description: after seeing a film about the procedure a face-to-face interview will take place
Study NCT03274336 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: movie
Description: after seeing a film about the procedure a face-to-face interview will take place
Study NCT01106534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
Study NCT01106534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel + aspirin OR prasugrel + aspirin
Description: This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
Study NCT01106534 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Description: XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
Study NCT01106534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Description: XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
Study NCT02929992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART initiation in the home
Description: Participants initiate ART use in the home without visiting a clinic
Study NCT02929992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Van Refill and Monitoring
Description: Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
Study NCT02929992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic ART Initiation
Description: Participants are referred to the clinic to initiate ART use
Study NCT02929992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic ART Initiation
Description: Participants are referred to the clinic to initiate ART use
Study NCT02929992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic ART Refill and Monitoring
Description: Participants will return to the clinic for ART refill and clinical monitoring.
Study NCT04207853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration em DM
Description: The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
Study NCT04207853 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vibration sham em DM
Description: Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
Study NCT03676790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I
Description: Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius).
Study NCT03676790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group II
Description: Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius).
Study NCT03676790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group III
Description: Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius).